A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Areas (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-020 [FOLLOW-UP OF 700046113]
Latest Information Update: 26 Mar 2013
Price :
$35 *
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Therapeutic Use
- 26 Mar 2013 New trial record
- 20 Mar 2013 Pooled results of long-term clearance rates were published in the Journal of the American Medical Association (JAMA) Dermatology, according to a LEO Pharma media release.